Financial Comparison: Statera Biopharma (NASDAQ:STAB) versus Aadi Bioscience (NASDAQ:AADI)

Aadi Bioscience (NASDAQ:AADI) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

Aadi Bioscience has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Institutional & Insider Ownership

52.1% of Aadi Bioscience shares are held by institutional investors. 35.8% of Aadi Bioscience shares are held by insiders. Comparatively, 5.5% of Statera Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Aadi Bioscience and Statera Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-270.04%	-52.53%	-44.29%
Statera Biopharma	N/A	N/A	N/A

Earnings & Valuation

This table compares Aadi Bioscience and Statera Biopharma’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$24.35 million	1.81	-$65.76 million	($2.44)	-0.74
Statera Biopharma	$1.49 million	0.02	-$101.85 million	N/A	N/A

Aadi Bioscience has higher revenue and earnings than Statera Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Aadi Bioscience and Statera Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0	1	1	0	2.50
Statera Biopharma	0	0	0	0	N/A

Aadi Bioscience currently has a consensus target price of $24.67, indicating a potential upside of 1,270.37%. Given Aadi Bioscience’s higher probable upside, analysts clearly believe Aadi Bioscience is more favorable than Statera Biopharma.

Summary

Aadi Bioscience beats Statera Biopharma on 8 of the 11 factors compared between the two stocks.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.